Reports Q2 revenue $5.06B, consensus $4.89B. “This was another excellent quarter – marked by exceptional top-line performance – that delivered margin expansion and prioritized investment for future growth,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific (BSX). “I am incredibly grateful to our dedicated global team for demonstrating clinical and commercial excellence across the company and positioning us for differentiated long-term performance.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Notable companies reporting before tomorrow’s open
- BSX Upcoming Earnings Report: What to Expect?
- Boston Scientific: Strong Growth Potential and Positive Outlook Justify Buy Rating
- Boston Scientific’s Sustained Growth and Margin Expansion Justify Buy Rating
- LAAX device study pause a positive update for Boston Scientific, says BofA